BDMD vs ISRG vs SYK vs NVCR

For growth investors, Intuitive Surgical, Inc.

(ISRG) is the stronger pick with 20. 5% revenue growth year-over-year, versus 8. 3% for NovoCure Limited (NVCR). Baird Medical Investment Holdings Limited (BDMD) offers the better valuation at 3. 8x trailing P/E, making it the more compelling value choice. Analysts rate Intuitive Surgical, Inc. (ISRG) a "Buy" — based on 55 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Baird Medical Investment Holdings Limited (BDMD) is the cheapest at 3.

8x versus Intuitive Surgical, Inc. at 57. 6x. On forward P/E, Stryker Corporation is actually cheaper at 19. 6x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Stryker Corporation wins at 1. 32x versus Intuitive Surgical, Inc. 's 2. 01x — a reasonable growth-adjusted valuation.

Over the past 5 years, Intuitive Surgical, Inc.

(ISRG) delivered a total return of +58. 7%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: ISRG returned +554. 2% versus BDMD's -80. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Stryker Corporation (SYK) is the lower-risk stock at 0.

55β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 303% more volatile than SYK relative to the S&P 500. On balance sheet safety, Intuitive Surgical, Inc. (ISRG) carries a lower debt/equity ratio of 2% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Intuitive Surgical, Inc.

(ISRG) is pulling ahead at 20. 5% versus 8. 3% for NovoCure Limited (NVCR). On earnings-per-share growth, the picture is similar: Intuitive Surgical, Inc. grew EPS 22. 6% year-over-year, compared to 8. 2% for Stryker Corporation. Over a 3-year CAGR, ISRG leads at 17. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Baird Medical Investment Holdings Limited (BDMD) is the more profitable company, earning 33.

6% net margin versus -20. 8% for NovoCure Limited — meaning it keeps 33. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BDMD leads at 41. 4% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — BDMD leads at 88. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Stryker Corporation (SYK) is the more undervalued stock at a PEG of 1. 32x versus Intuitive Surgical, Inc. 's 2. 01x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Stryker Corporation (SYK) trades at 19. 6x forward P/E versus 43. 8x for Intuitive Surgical, Inc. — 24. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 99. 0% to $33. 50.

In this comparison, SYK (1.

1% yield) pays a dividend. BDMD, ISRG, NVCR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Stryker Corporation (SYK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

55), 1. 1% yield, +187. 1% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SYK: +187. 1%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: BDMD is a small-cap high-growth stock; ISRG is a mid-cap high-growth stock; SYK is a mid-cap quality compounder stock; NVCR is a small-cap quality compounder stock. SYK pays a dividend while BDMD, ISRG, NVCR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.